Fully reconstituted immunodeficient mice with CD34+ HSCs isolated from patients with IL-10R mutations are not suitable for assessing the therapeutic biologics aiming at developing interventional approaches against IBD. Here, IL10RA is linked to inflammatory bowel disease.